Patents by Inventor Marc F. Pelletier
Marc F. Pelletier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11873266Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: July 26, 2021Date of Patent: January 16, 2024Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H Hall, Walter F. Boron
-
Patent number: 11801254Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: GrantFiled: November 16, 2020Date of Patent: October 31, 2023Assignee: Aeromics, Inc.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr
-
Publication number: 20220143048Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: June 16, 2021Publication date: May 12, 2022Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Publication number: 20220081391Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: July 26, 2021Publication date: March 17, 2022Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Publication number: 20210275549Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: ApplicationFiled: November 16, 2020Publication date: September 9, 2021Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
-
Patent number: 11084778Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: May 17, 2018Date of Patent: August 10, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 11071744Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: GrantFiled: October 28, 2019Date of Patent: July 27, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Patent number: 10894055Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: GrantFiled: December 31, 2018Date of Patent: January 19, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr
-
Publication number: 20200297740Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: October 28, 2019Publication date: September 24, 2020Applicant: AEROMICS, INC.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Robert ZAMBONI, John COLUCCI, Helmi ZAGHDANE
-
Publication number: 20190307779Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: ApplicationFiled: December 31, 2018Publication date: October 10, 2019Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
-
Patent number: 10258636Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: GrantFiled: October 24, 2017Date of Patent: April 16, 2019Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Publication number: 20180334424Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: May 17, 2018Publication date: November 22, 2018Inventors: Marc F. PELLETIER, George William FARR, Paul Robert MCGUIRK, Christopher H. HALL, Walter F. BORON
-
Publication number: 20180169118Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: October 24, 2017Publication date: June 21, 2018Applicant: AEROMICS, INC.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Robert ZAMBONI, John COLUCCI, Helmi ZAGHDANE
-
Patent number: 9994514Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: May 8, 2013Date of Patent: June 12, 2018Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 9949991Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., glioblastoma and ovarian hyperstimulation syndrome. The invention provides, inter alia, methods of treating or controlling a disease condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.Type: GrantFiled: November 6, 2014Date of Patent: April 24, 2018Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Steven Williams
-
Publication number: 20180042873Abstract: Provided are uses of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the treatment or prophylaxis of transplant rejection and the protection of the heart during heart surgery. Provided is the use of selective aquaporin inhibitors, e.g., of aquaporin-4 (AQP4) or aquaporin-2 (AQP2) for the treatment or prophylaxis of transplant rejection and for the protection of the heart during heart surgery.Type: ApplicationFiled: November 13, 2015Publication date: February 15, 2018Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, George William FARR, Paul Robert MCGUIRK
-
Patent number: 9827253Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: GrantFiled: November 6, 2014Date of Patent: November 28, 2017Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Patent number: 9573885Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: June 27, 2015Date of Patent: February 21, 2017Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Publication number: 20160346302Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., glioblastoma and ovarian hyperstimulation syndrome. The invention provides, inter alia, methods of treating or controlling a disease condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.Type: ApplicationFiled: November 6, 2014Publication date: December 1, 2016Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Steven WILLIAMS
-
Publication number: 20160279155Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof. Also provided are kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate. Also provided is a method of treating or controlling a disease or condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.Type: ApplicationFiled: November 6, 2014Publication date: September 29, 2016Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR